831. Current Thoughts on the Optimal Duration of Treatment of Bloodstream Infections: How Long Is Long Enough?
Session: Symposium: Questions in Bacteremia: What's Old Is New Again
Thursday, October 27, 2016: 3:00 PM
Room: 293-296
Vance G. Fowler Jr., MD, Duke University Medical Center, Durham, NC

Disclosures:

V. G. Fowler Jr., Pfizer, Novartis, Galderma,: Consultant , Consulting fee
Novadigm, Durata, Debiopharm,: Consultant , Consulting fee
Genentech, Achaogen, Affinium,: Consultant , Consulting fee
Medicines Co., Cerexa, Tetraphase,: Consultant , Consulting fee
Trius, MedImmune, Bayer,: Consultant , Consulting fee
Theravance, Cubist, Basilea,: Consultant , Consulting fee
Affinergy, Janssen, Novartis: Consultant , Consulting fee
Grant Investigator , Research grant
NIH: Grant Investigator , Research support
MedImmune: Grant Investigator , Research grant
Pfizer, Theravance, Karius: Grant Investigator , Research grant
Advanced Liquid Logics: Grant Investigator , Research grant
Novartis, Cubist/Merck: Grant Investigator , Research grant
Medical Biosurfaces: Grant Investigator , Research grant
Locus, Affinergy, Contrafect: Grant Investigator , Research grant
Green Cross: guest speaker , Speaker honorarium
UpToDate: Author , Royalties
Patent Pending - diagnostics: partial owner of patent pending sepsis diagnostics , partial owner of patent pending sepsis diagnostics

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.